Talis Biomedical Corp. (TLIS) Business Payback Period

Corporate emblem and logo of Talis Biomedical Corp (TLIS)

Talis Biomedical (TLIS) develops rapid tests by outsourcing the assembly of Talis One analyzers through US contractors. This price chart on GURU.Markets with the -0.20 indicator confirms the current trend. However, sanctions and disruptions in Asian electronics supplies are increasing production costs. The company is currently in a financial crisis, liquidating assets and shutting down development projects amid depleting capital.

TLIS: Talis Biomedical Corporation P/E Multiple 07/04/2022 - 09/07/2024

Analytical breakdowns for Talis Biomedical Corp. (TLIS)

- market price and analyst price targets:
Market Price Talis Biomedical Corp|TLIS - Price Target Chart
- market capitalization details:
Market Capitalization Talis Biomedical Corporation|TLIS - Real Price to Acquire Entire Company
- book capitalization data:
Book Price of a Share Talis Biomedical|TLIS - Book Capitalization|Market Capitalization to Book Value talis.bio|TLIS - Company Total Assets
- debt obligations and liquidity statistics:
Total Debt to Equity Ratio Talis Biomedical|TLIS - Long-Term Debt to Equity Ratio|Ratio of Short-Term Indebtedness to Capital Talis Biomedical Corp|TLIS - Company Debts|Debt to Book Value Talis Biomedical Corporation|TLIS - Company Long-Term Debts|Short-Term Debt Talis Biomedical|Immediate Liquidity Ratio talis.bio
- earnings and valuation multiples information:
TLIS - Net Profit|Company Profit Forecast Talis Biomedical|TLIS - P/E Multiple|Projected Price to Earnings Talis Biomedical Corp|TLIS - PEG Multiple|EV/EBITDA Multiple Talis Biomedical Corporation|TLIS - Profit before payment of interest, taxes and amortization|Earnings per share for the last twelve months Talis Biomedical|TLIS - Net earnings per share for the last 12 months|Year-over-year earnings per one share growth for the last 12 months talis.bio|TLIS - Earnings growth in current year|Expected net earnings per share growth next year Talis Biomedical
Comprehensive company analysis:TLIS talis.bio
Signature product of Talis Biomedical

The P/E ratio is calculated as the ratio of current market capitalization to the company's net income. This metric determines the cost of one dollar of profit, reflecting market expectations for business growth rates. For Talis Biomedical (TLIS), this indicator loses its classical meaning due to the complete cessation of commercial activities and R&D. The absence of operational development renders the company's fundamental P/E an indicator of speculative sentiment. Analyzing this chart helps identify overpayment for non-performing assets.

Key competitors

Market Cap to Earnings abbott.com ABT|Price to Earnings Ratio Thermo Fisher (TMO)|Business Payback Period GE HealthCare Technologies Inc.|Mettler-Toledo International Inc. - Price to Earnings Ratio|Market Price to Net Income Ratio WAT (Waters Technologies)|Bio-Techne Corporation - P/E Multiple|Business Payback Period bruker.com BRKR|AZTA: P/E Multiple|Price to Earnings Ratio Varex Imaging Corp|Price to Earnings Ratio SMLR|BFLY: Company Value to Net Income|Price to Earnings Ratio Mesa Laboratories, Inc. (MLAB)|Price to Earnings Ratio quantum-si.com QSI|P/E Multiple NNOX (Nano-X)|Quanterix Corp. (QTRX) - Market Cap to Earnings|908 Devices Corp - P/E Multiple|CV (CapsoVision Inc) - Price to Earnings Multiple|MXCT: P/E Multiple|RPID - Business Payback Period|SEER (Seer) - P/E Multiple|Price to Earnings Ratio Hyperfine Inc (HYPR)|P/E Multiple FONR|P/E Multiple daxor.com (DXR)|Price to Earnings Ratio Spectral AI MDAI|organovo.com - Price to Earnings Ratio|ACON: Price to Earnings Ratio|Company Value to Net Income AKYA (Akoya Biosciences)|THMO: P/E Multiple|Market Cap to Earnings T2 Biosystems Inc (TTOO)